Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.39 |
| ▸ | COPS5 | Q92905 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.37 |
| ▸ | GFER | P55789 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13836388 | 0.76 | KMT2A (0.48) | KMT2AMAPK1L3MBTL1MEN1TDP1 | |
| SCHEMBL61427 | 0.74 | MAPT (0.48) | KMT2AMAPK1L3MBTL1MEN1TDP1 | |
| SCHEMBL6390857 | 0.73 | KMT2A (0.46) | KMT2AMAPK1L3MBTL1MEN1TDP1 | |
| SCHEMBL1172982 | 0.73 | KMT2A (0.46) | KMT2AMAPK1L3MBTL1MEN1TDP1 | |
| SCHEMBL762439 | 0.73 | KMT2A (0.65) | KMT2AMAPK1L3MBTL1MEN1TDP1 | |
| SCHEMBL10305615 | 0.73 | KMT2A (0.46) | KMT2AMAPK1L3MBTL1MEN1TDP1 | |
| SCHEMBL57595 | 0.73 | KMT2A (0.46) | KMT2AMAPK1L3MBTL1MEN1TDP1 | |
| SCHEMBL5543675 | 0.73 | ACHE (0.54) | KMT2AMAPK1L3MBTL1MEN1TDP1 | |
| SCHEMBL1820230 | 0.73 | KMT2A (0.46) | KMT2AMAPK1L3MBTL1MEN1TDP1 | |
| SCHEMBL1109057 | 0.72 | KMT2A (0.46) | KMT2AMAPK1L3MBTL1MEN1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240148723-A1 | MYCOBACTERIUM TUBERCULOSIS COMPOSITIONS AND METHODS | PZA INNOVATION LLC | 2024-05-09 | — | — | US | disclosed |
| WO-2023225244-A1 | HETEROCYCLIC COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE | BIOGEN MA INC. (US) | 2023-11-23 | — | — | WO | disclosed |
| EP-2516445-B1 | TRICYCLIC DERIVATIVES AND THEIR PHARMACEUTICAL USE AND COMPOSITIONS | CEPHALON INC (US) | 2015-03-11 | — | — | EP | disclosed |
| US-8765779-B2 | Tricyclic derivatives and their pharmaceutical use and compositions | CEPHALON, INC. (US) | 2014-07-01 | — | — | US | disclosed |
| US-20120295882-A1 | Tricyclic Derivatives and Their Pharmaceutical Use and Compositions | CEPHALON, INC. (US) | 2012-11-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120295882-A1 | Tricyclic Derivatives and Their Pharmaceutical Use and Compositions | CYP3A43, CYP3A7, CYP2C19 | KMT2A 4588/4885MAPK1 3942/4885L3MBTL1 4877/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.